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Objectives: This study evaluated cost-effectiveness of posaconazole versus 
standard azole therapy (SAT; fluconazole or itraconazole) for prevention of inva-
sive fungal infection (IFI) in neutropenic patients from the Thai health care 
system perspective. MethOds: A decision-analytic model was developed based 
on data from clinical trials. The surviving patients in the decision tree were 
extrapolated to a lifetime horizon using Markov model in which mortality risk 
was specific to underlying disease. The rates of IFI, IFI-related mortality, overall 
mortality and treatment duration were obtained from published literature. The 
probability of IFI-related death of posaconazole was assumed to be equal to 
SAT for Scenario I (45%), and was lower than SAT for Scenario II (36% vs. 48%) as 
obtained from clinical trial. Data of IFI-related costs and health care resource 
utilization were obtained from local studies and expert opinion. Drug prices 
were those published by Ministry of Public Health. All costs were expressed in 
THB 2013 values. Future costs and outcomes were discounted at 3%. The model 
outcomes included costs, IFI avoided, life years saved (LYS) and incremental 
cost-effectiveness ratio (ICER) of posaconazole versus SAT. Results: In com-
parison with fluconazole/itraconazole, posaconazole was associated with fewer 
IFIs per patient (0.05 vs. 0.11) during 100-day follow-up. Over a lifetime horizon, 
prophylaxis with posaconazole resulted in lower discounted costs and a benefit 
of 0.06 and 0.07 in terms of discounted LYS for Scenario I and II, respectively. 
The probabilistic sensitivity analyses showed that there are 95.9% and 96.4% 
probabilities that posaconazole is cost-effective relative to fluconazole/itra-
conazole at the recommended threshold of 160,000 THB/LYS for such compari-
sons. cOnclusiOns: This analysis suggested that posaconazole is the dominant 
treatment strategy (more effective and less costly) for the prevention of IFI in 
patients with prolonged neutropenia in Thailand. Posaconazole prophylaxis may 
substantial diminish for the economic burden of IFI.
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Objectives: Dengue fever is a vector-borne disease prevalent in tropical and sub-
tropical regions. It is an important public health problem with a considerable and 
often under-valued disease burden in terms of frequency, cost and quality-of-life. 
Previous analyses have documented the cost-effectiveness of vaccination as well 
as a range of vector-control interventions. However, such analyses do not evaluate 
the cost-effectiveness of combined vaccination and vector control interventions. 
We seek to demonstrate the public health and economic value of interventions 
compared with the next best alternative embracing both vaccination as well as 
vector-control interventions. MethOds: Using a previously published dynamic 
compartmental model (Knerer 2013) able to consider dengue fever transmission, 
we assessed the impact of different vector-control, vaccination and mixed strate-
gies. We then combined the results with economic data to estimate the relative 
cost-effectiveness of dengue vector-control and vaccination strategies in different 
age-groups in Thailand. We estimated the expected costs and outcomes of indi-
viduals with dengue fever (vaccinated or not). Costs included direct medical costs 
such as the costs of vaccination, costs of hospitalisation, as well as the indirect 
costs of lost productivity. The health burden of dengue fever was assessed in rela-
tion to disability-adjusted life-years (DALYs) lost. Results: We found vaccination 
to be a cost-effective single intervention, both with imperfect efficacy (30.2%) 
as well as under more optimistic scenarios (70%). Cost-effectiveness ratios for 
vector-control strategies ranged from being cost-effective and even cost saving 
to cost ineffective with incremental cost-effectiveness ratios in excess of  WHO 
guidelines. In combination, control interventions and vaccination exhibited a 
marked impact on dengue fever transmission and proved to be a cost-effective 
strategy as well as delivering the potential for cost-savings. cOnclusiOns: By 
providing a high level of disease control, the implementation of a vaccination 
program in combination with vector-control strategies appears to be cost-effective 
and often cost-saving.
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Objectives: This study aims to assess the cost-effectiveness of hepatitis A vac-
cination in Indonesia, including an explicit comparison between one-dose and two-
dose vaccines. MethOds: An age-structured cohort model based on a decision 
tree was developed for the 2012 Indonesia birth cohort. Using the model, we made 
a comparison on the use of two-dose and one-dose vaccines. The model involves 
a 70-year time horizon with 1-month cycles for children less than 2 years old and 
annually thereafter. Monte Carlo simulations were used to examine the economic 
acceptability and affordability of the hepatitis A vaccination. Results: With the 
vaccine price of US$ 4.49 per dose, the implementation of the hepatitis A vaccine 
from the societal perspective would yield incremental-cost-effectiveness-ratios 
(ICERs) at US$ 9,194 and US$ 4,577 for the two-dose and one-dose vaccine sched-
ules, respectively. Considering the 2012 gross-domestic-product (GDP) per capita in 
Indonesia of US$ 3,557, the results indicate that hepatitis A vaccination would be 
a cost-effective intervention, both for the two-dose and one-dose vaccine sched-
ules. Vaccination would be 100% affordable at budgets of US$ 89,918,000 and US$ 
46,778,000 for the implementation of the two-dose and one-dose vaccine sched-
ules, respectively. cOnclusiOns: The implementation of hepatitis A vaccination 
in Indonesia would be a cost-effective health intervention under the market vaccine 
prices. Given the budget limitations, the use of a one-dose-vaccine schedule would 
be more realistic to be applied than a two-dose schedule. The discount rate, vac-
cine price, vaccine efficacy and mortality rate were the most influential parameters 
impacting the ICERs.
disease incidence and serotype coverage and health care utilization to compare 
costs and clinical impact of PCV-13 versus PCV-10 on IPD, inpatient and outpatient 
pneumonia, and AOM , among vaccinated children (direct effect) and the entire 
population with indirect(herd effects). Patients were entered in the model by age 
groups: ages 0-< 2 years, 2-4 years, 5-17 years, 18-34 years, 35-49 years, 50-64 years, 
65+ years. Only 0-2 year cohort was vaccinated. The local epidemiology and cost 
data were used to achieve national specificity. Direct/Indirect effectiveness of PCV-
13 and PCV-10 were calculated based on PCV-7 efficacy data, using assumptions 
regarding serotype coverage and PCV-10 and PCV-13 protection against additional 
serotypes. Results: In the analysis, PCV-13 vaccination has caused significant 
decline in all PD cases. It was estimated to prevent 19,918 cases of IPD, 3,796,657 
cases of pneumonia, and 53,310,807 cases of AOM in 10-year cohort. Also the incre-
mental cost per LYG was estimated at 10,043,048 won for the PCV-13 vaccination 
from the health care system perspective in the 10-year horizon, as compared to 
PCV-10 vaccination. cOnclusiOns: PCV-13 vaccination program provided eco-
nomic and clinical impact on overall PD prevention and cost-effective compared 
with PCV-10 vaccination.
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Objectives: Despite routine vaccination, pertussis remains an important 
public health problem with an increase in annual incidences worldwide in 
recent years. Since infants too young to be protected by vaccination remain at 
risk of severe pertussis-related morbidity, New Zealand Authorities recommended 
and funded maternal immunisation against pertussis in 2013. In this study, we evalu-
ated the cost-effectiveness of adding a maternal immunisation program to routine 
vaccination prior to 2013 in New Zealand. MethOds: A decision-tree model was 
adapted from the literature. A cohort of infants below 1 year of age (corresponding 
to the birth cohort in New Zealand) and a cohort with their mothers are followed. 
Data on pertussis morbidity and costs were gathered for infants and their mothers. 
Health benefits (in quality-adjusted life-years [QALYs]) and costs were estimated. 
Incremental cost-effectiveness ratio was calculated from a payer’s perspective. The 
robustness of results was determined through scenario analysis (years of low, high 
and average incidence) and sensitivity analysis. Results: In the base-case analysis 
(average incidence 2009-2012, 20% coverage, 1:100 underreporting), maternal immuni-
sation was found to reduce the incidence of pertussis among infants (62 infant cases 
prevented) and was estimated to have a cost-effectiveness ratio of NZD 527.17/QALY 
from a payer’s perspective. During a high incidence year maternal immunisation 
was dominant. During a low incidence year maternal immunisation was estimated 
to have a cost-effectiveness ratio below NZD 32,577.42/QALY. In the scenario analysis, 
the cost-effectiveness of maternal immunisation remained below that ratio and even 
dominant in most cases. cOnclusiOns: This study estimated that the addition of 
maternal immunisation to the New Zealand national immunisation program was a 
cost-effective or even cost-saving decision. DISCLAIMER: This is a cost-effectiveness 
study only. There is currently no pertussis immunisation indication/label for preg-
nancy in New Zealand and any immunisation should be consistent with local product 
labelling.
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Objectives: Hepatitis C virus (HCV) is currently affecting more than 43 million 
persons in China, but the high cost of the standard drug therapy with pegylated 
interferon (PEG-IFN) inhibits many HCV infected patients to obtain appropriate treat-
ment. A newly developed domestic low-price PEG-IFN (Peginterferonalfα -2b (40kD, 
Y shape) is expected to benefit the patients greatly with an equally effective treat-
ment at substantially lower cost. This study provides the first scientific analysis to 
report the cost-effectiveness of this new drug treatment which is expected to be 
soon available for HCV infected patients in China. MethOds: Data was obtained 
from a multicenter, open and randomized, effective drug controlled phase 3 clinical 
trial. 242 eligible patients were randomized into the treatment group (PEG-IFNα -2b 
(40kD, Y shape) combined with RBV) and the control group (PEG-IFNα -2a combined 
with RBV). The effectiveness measure was sustained viral response (SVR). Costs, 
which were measured by direct medical costs, were obtained from medical records. 
An incremental cost-effectiveness ratio was calculated and probabilistic sensitivity 
analysis was conducted based on bootstrapping method. Results: The SVR rate of 
PEG-IFNα -2b(40kD, Y shape) cohort and PEG-IFNα -2a cohort were 85.44% and 79.52% 
(p= 0.2419) respectively. In the meantime, patients receiving PEG-IFNα -2b(40kD, Y 
shape) incurred significantly less costs compared to the PEG-IFNα -2a treated control 
group (CNY 29930.74 vs. 36743.90, P< 0.01). cOnclusiOns: Compared to PEG-IFNα -2a 
treatment, PEG-IFNα -2b (40kD, Y shape) treatment is equally effective at substantially 
lower costs. Sensitivity analysis conducted with bootstrapping method indicts a great 
possibility that PEG-IFNα -2b (40kD, Y shape) treatment is a cost-saving therapy.
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